Julie Bailis
Associate Vice President Research, Amgen Inc.
Julie Bailis
Associate Vice President Research, Amgen Inc.
Product: IMDELLTRA® (tarlatamab-dlle)
Company: Amgen Inc.
About the Product:
Small cell lung cancer is one of the most aggressive solid tumor malignancies, with a 5-10% five-year relative survival rate across all stages combined. Despite initial high response rates to first-line chemotherapy, most patients quickly relapse. IMDELLTRA® (tarlatamab-dlle) is used to treat adults with small cell lung cancer that has spread, and who have received treatment with certain types of chemotherapy. IMDELLTRA is a first-in-class immunotherapy that utilizes BiTE® (Bispecific T-cell Engager) technology to redirect the body’s immune system to attack tumors. IMDELLTRA binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to fight DLL3-expressing SCLC cells. DLL3 is a protein that is expressed on the surface of tumor cells in up to 96% of patients with SCLC, making it an exciting target.
Jason Richardson
Director, Clinical Research, Clinical Strategy & Epidemiology, Bavarian Nordic
Jason Richardson
Director, Clinical Research, Clinical Strategy & Epidemiology, Bavarian Nordic
Product: VINKUNYA (Chikungunya Vaccine, Recombinant)
Company: Bavarian Nordic
About the Product:
VIMKUNYA™ (chikungunya vaccine, recombinant) is an FDA-approved, single-dose vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older. It is the first and only virus-like particle (VLP) vaccine recommended by the U.S. Advisory Committee on Immunization Practices (ACIP) for chikungunya. VIMKUNYA contains proteins that assemble into VLPs, which mimic the chikungunya virus but cannot infect cells or cause disease.
Richard Daly
President and Chief Executive Officer, Catalyst Pharmaceuticals
Richard Daly
President and Chief Executive Officer, Catalyst Pharmaceuticals
Product: AGAMREE®
Company: Catalyst Pharmaceuticals
About the Product:
AGAMREE® was developed to uncouple the anti-inflammatory effects of corticosteroids commonly used in Duchenne Muscular Dystrophy (DMD) from certain side effects. It is a corticosteroid with a novel structure, designed to retain strong anti-inflammatory action. AGAMREE is structurally unique compared with corticosteroids commonly used to treat DMD. Like those corticosteroids, it inhibits the activity of a protein complex that plays a key role in the inflammatory process. AGAMREE is clinically proven to improve muscle strength and function in boys with DMD and is FDA-approved for the treatment of DMD in patients 2 years of age and older.
Deepu Madduri
Compound Development Team Leader Johnson & Johnson Services, Inc.
Deepu Madduri
Compound Development Team Leader Johnson & Johnson Services, Inc.
Product: CARVYKTI®
Company: Johnson & Johnson and Legend Biotech
About the Product:
CARVYKTI ® is a BCMA-directed, genetically modified autologous T-cell immunotherapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. The treatment involves reprogramming a patient’s own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs T-cells to eliminate cells that express BCMA. CARVYKTI is redefining the patient experience by delivering extraordinary efficacy and a manageable safety profile as a one-time infusion.
Jaszianne Tolbert
Executive Medical Director, Oncology R&D, Johnson & Johnson Services, Inc.
Jaszianne Tolbert
Executive Medical Director, Oncology R&D, Johnson & Johnson Services, Inc.
Product: TALVEY™
Company: Johnson & Johnson Services, Inc.
About the Product:
TALVEY® is a first-in-class bispecific T-cell engaging antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. TALVEY targets CD3 on T cells and GPRC5D on myeloma cells, directing T cells to attack these cells. It is being explored in combination with other therapies, including proteasome inhibitors, immunomodulatory drugs, and other novel agents, reinforcing its versatility in managing multiple myeloma for this patient population who face limited treatment options.
Margaret Doyle
Senior Global Medical Affairs Leader, Oncology, Johnson & Johnson Services, Inc.
Margaret Doyle
Senior Global Medical Affairs Leader, Oncology, Johnson & Johnson Services, Inc.
Product: TECVAYLITM
Company: Johnson & Johnson
About the Product:
TECVAYLI® is a first-in-class, bispecific T-cell engager antibody therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. TECVAYLI® uses innovative science to activate the immune system by binding to both the CD3 receptor expressed on the surface of T-cells and the B-cell maturation antigen (BCMA) on the surface of multiple myeloma cells and some healthy B-lineage cells. As the first approved off-the-shelf BCMA×CD3 bispecific therapy with a personalized weight-based dosing schedule, TECVAYLI® enables deep and durable responses with a manageable tolerability profile.
Ana Sanchez
Senior Product Manager, MGI Tech
Ana Sanchez
Senior Product Manager, MGI Tech
Product: DNBSEQ-T20
Company: MGI Tech
About the Product:
DNBSEQ-T20 is the first and only one product in the world which drops genome sequencing price to sub $100, while the average in the field is still on $200 or more. In order to gather health data around the world, researchers needed a standardized collection process of clinic and hospital data and databases. However, large-scale whole genome sequencing technologies are difficult to carry out. Over the years, researchers have made great strides to drive the science forward. From higher throughput to greater data accuracy and efficiency, genomics companies nationwide have been working hard to push the boundaries of sequencing technologies.
Thomas Lehmann
Vice President, Global Program Head (Scemblix + CML/MPN), Novartis
Thomas Lehmann
Vice President, Global Program Head (Scemblix + CML/MPN), Novartis
Product: SCEMBLIX®
Company: Novartis
About the Product:
Kena Swanson
Vice President, Head, Viral Vaccines, Pfizer Inc.
Kena Swanson
Vice President, Head, Viral Vaccines, Pfizer Inc.
Product: ABRYSVO®
Company: Pfizer
About the Product:
A vaccine to help prevent respiratory syncytial virus (RSV) had been an elusive public health goal for more than half a century. Pfizer’s ABRYSVO® is the only RSV vaccine that helps protect two of the most vulnerable populations: adults 60 years of age and older, as well as infants from birth through six months through maternal immunization. ABRYSVO is a bivalent vaccine that provides protection against lower respiratory tract disease caused by the respiratory syncytial virus, inclusive of both major subgroups RSV-A and RSV-B. ABRYSVO continues Pfizer’s commitment to helping prevent serious respiratory disease in infants and older adults.
Dana Kennedy
Genitourinary Cancers TA Development Head, Pfizer Inc.
Dana Kennedy
Genitourinary Cancers TA Development Head, Pfizer Inc.
Product: PADCEV®
Company: Pfizer Inc./Astellas
About the Product:
Pfizer has transformed this landscape with PADCEV, which, combined with pembrolizumab, has been shown to nearly double the median overall survival for adults with locally advanced or metastatic urothelial carcinoma (la/mUC) in first-line treatment.i It is also approved alone (or as a monotherapy) in second-line treatment for patients with la/mUC who have previously received a PD-(L)1 inhibitor and a platinum-containing chemotherapy. PADCEV, in combination with pembrolizumab, now a standard of care for first-line treatment of la/mUC, is being studied in ongoing trials in patients with muscle invasive bladder cancer (MIBC).